. Author manuscript; available in PMC: 2024 Sep 27.

Published in final edited form as: JACC Heart Fail. 2023 Aug;11(8 Pt 2):1055–1069. doi: 10.1016/j.jchf.2023.07.016

TABLE 1.

Effectiveness of MitraClip in Reducing MR in Clinical Trials

	Years Enrolled	Type of MR	N	MitraClip Generation System	≤2+ Residual MR at 1 Year (%)	≤1+ Residual MR at 1 Year (%)

EVEREST II RCT (PMID: 21463154)	2005–2008	Primary (73%) and secondary MR	184	NT (G1)	82	43
Everest II Realism registry (PMID: 30586701)	2005–2013	Secondary MR	616	NT (G1)	84.5	42.9
MITRA-FR	2013–2017	Secondary MR	152	NT (G2)	83.0	49.5
COAPT trial	2013–2017	Secondary MR	302	NT (G2)	94.8	69.1
EXPAND prospective registry	2018–2019	Primary and secondary MR (~50/50)	509	G3	96.0	83.5
EXPAND Secondary MR	2018–2019	Secondary MR	213	G3	99.1	89.5

COAPT = Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation; EVEREST = Endovascular Valve Edge-to-Edge Repair Study; EXPAND = A Contemporary, Prospective, Multi-Center Study Evaluating Real-World Experience of Performance and Safety for the Next Generation of MitraClip Devices; MR = mitral regurgitation; PMID = PubMed identifier; RCT = randomized controlled trial.